Cargando…

Correction: Preparing for the incoming wave of biosimilars in oncology

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212677/ https://www.ncbi.nlm.nih.gov/pubmed/30425848 http://dx.doi.org/10.1136/esmoopen-2018-000420corr1

Ejemplares similares

Preparing for the incoming wave of biosimilars in oncology
por: Wolff-Holz, Elena, et al.
Publicado: (2018)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Correction to: SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Biosimilars in oncology
por: Tabernero, Josep
Publicado: (2018)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Correction to: MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2022)

Correction to: To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
por: Rezk, Mourad F., et al.
Publicado: (2018)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2023)

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Correction: Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis
por: Venetis, Christos A., et al.
Publicado: (2023)

Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015)

Correction to: Assessing the prevalence of young children living in households prepared for COVID-19 in 56 low- and middle-income countries
por: Lu, Chunling, et al.
Publicado: (2022)

Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
por: Mansell, Kerry, et al.
Publicado: (2019)

Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation
por: Martino, Massimo, et al.
Publicado: (2023)

Barriers to Oncology Biosimilars Uptake in the United States
por: Nabhan, Chadi, et al.
Publicado: (2018)

The role of biosimilars in value-based oncology care
por: Patel, Kashyap B, et al.
Publicado: (2018)

Development of biosimilars in an era of oncologic drug shortages
por: Li, Edward, et al.
Publicado: (2015)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

Current and future roles of biosimilars in oncology practice
por: Konstantinidou, Sofia, et al.
Publicado: (2020)

Biosimilars in Oncology: Latest Trends and Regulatory Status
por: Joshi, Deeksha, et al.
Publicado: (2022)

Oncology biosimilars: New developments and future directions
por: Bachu, Rinda Devi, et al.
Publicado: (2022)

Correction to: Precision medicine in pediatric oncology
por: Burdach, Stefan E. G., et al.
Publicado: (2022)

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
por: Strand, Vibeke, et al.
Publicado: (2020)

Correction: Clinical emergency care research in low-income and middle-income countries: opportunities and challenges
Publicado: (2020)

Presently available biosimilars in hematology-oncology: G-CSF
por: Gascon, Pere
Publicado: (2012)

Biosimilar agents in oncology/haematology: from approval to practice
por: Niederwieser, Dietger, et al.
Publicado: (2011)

Biosimilars in the United States: Considerations for Oncology Advanced Practitioners
por: Mayden, Kelley D., et al.
Publicado: (2015)

Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner
por: Campen, Christopher J.
Publicado: (2017)

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology
por: Giuliani, Rosa, et al.
Publicado: (2019)

Correction to: Assessment of the cost of the Mediterranean diet in a low-income region: adherence and relationship with available incomes
por: Rubini, Alessia, et al.
Publicado: (2022)

Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
por: Markus, Richard, et al.
Publicado: (2017)

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2‑positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Author Correction: Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males
por: Liu, Hui, et al.
Publicado: (2021)

Correction to: Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review
por: Rezk, Mourad F., et al.
Publicado: (2020)

Correction: The White Ceiling Heuristic and the Underestimation of Asian-American Income
Publicado: (2014)

Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
por: Remon, J., et al.
Publicado: (2020)

The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
por: Fernandes, G.S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r1icapcjklo91n2qjtjdusm882